Drones accelerate this loop dramatically. Lightweight, autonomous, and capable of 30-to-60-minute service, they slash last-mile costs while simultaneously creating a proprietary, real-time training dataset no competitor can replicate at scale. What begins as a logistics upgrade ends up supercharging AWS workloads and AI capabilities — turning physical movement into digital intelligence that improves every other part of the business.

Nowhere does this flywheel spin with greater force than in Amazon Pharmacy. Prescription delivery is the ideal payload: small, lightweight, high-margin, and extremely time-sensitive. When a customer needs medication for pain, infection, or chronic conditions, “under one hour” is not a nice-to-have convenience — it is a trust event. Once patients experience the reliability of same-day or sub-hour drone or ultra-fast ground delivery, switching costs skyrocket. They refill prescriptions automatically, add family members to the account, and lean on Amazon for related health products. Usage frequency is high and recurring. Each interaction feeds the data engine with patterns that improve routing, demand forecasting, and even supply-chain resilience for temperature-sensitive drugs.

The result is a high-trust, high-frequency service that compounds exponentially. Prime members already enjoy discounted generics and transparent pricing; layer on drone-enabled urgency and the habit becomes sticky at a level traditional retail pharmacies cannot match. Logistics efficiency funded by AWS lowers costs, AI sharpens execution, and the resulting customer lock-in drives incremental e-commerce spend elsewhere on the platform. What looks like “just another delivery vertical” is quietly becoming one of Amazon’s most powerful economic moats.

Prime Air’s evolution from mocked concept to operational reality exemplifies the flywheel’s power. Regulatory approvals, technological maturation, and AWS-backed capital have enabled Amazon to launch Prime Air drone deliveries in select markets, though broad scalability is still pending further regulatory clearance.

Jassy’s bullish forecast — roughly 500 million annual deliveries by the end of the decade — signals that aerial logistics will soon move from experimental to material. Each successful flight not only delights customers but also tightens the data-AI loop, funding further expansion. The virtuous cycle is no longer theoretical; it is airborne.

E-commerce scale, AWS profitability, and flashy AI initiatives continue to suck all the oxygen out of investor conversations about Amazon. Yet the pharmacy business — currently a modest contributor generating an estimated $2 billion in annual revenue against Amazon’s $717 billion total in 2025 — stands poised as the hidden asset for explosive near-term growth.

As drone and ultra-fast delivery networks mature and the flywheel turns faster, Amazon Pharmacy can capture a far larger slice of the $634 billion U.S. pharmacy market. High-trust, high-frequency prescription service will drive Prime stickiness, generate proprietary health-adjacent data, and deliver outsized margins.

The real story at Amazon is not just what is visible in the cloud or on the website — it is what is quietly landing on doorsteps, one prescription at a time. Investors who connect these dots may find the stock’s most compelling upside still hiding in plain sight.

Wall Street is pouring billions into AI, but most investors are buying the wrong stocks. The analyst who first identified NVIDIA as a buy back in 2010 — before its 28,000% run — has just pinpointed 10 new AI companies he believes could deliver outsized returns from here. One dominates a $100 billion equipment market. Another is solving the single biggest bottleneck holding back AI data centers. A third is a pure-play on an optical networking market set to quadruple. Most investors haven’t heard of half these names. Get the free list of all 10 stocks here.